XML 18 R21.htm IDEA: XBRL DOCUMENT v3.19.3.a.u2
Segment and Enterprise Wide Disclosures
9 Months Ended
Dec. 31, 2019
Segment Reporting [Abstract]  
Segment and Enterprise Wide Disclosures

Note 14. Segment and Enterprise Wide Disclosures

The Company operates in one business segment: the research, development and sale of medical devices to assist or replace the pumping function of the failing heart. The Company’s chief operating decision maker (determined to be the Chief Executive Officer) does not manage any part of the Company separately, and the allocation of resources and assessment of performance are based on the Company’s consolidated operating results. International sales (meaning sales outside the U.S., primarily in Europe and Japan) accounted for 16% and 14% of total revenue for the three months ended December 31, 2019 and 2018, respectively, and 16% and 13% of total revenue for the nine months ended December 31, 2019 and 2018, respectively. The Company’s long-lived assets are located in the U.S., except for $46.6 million and $43.4 million at December 31, 2019 and March 31, 2019, respectively, which are located primarily in Germany.